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ABSTRACT 
A simple precise and economical reverse phase high performance liquid chromatographic method has been developed and validated for the 
simultaneous estimation of Cilnidipine (CDP), Atenolol (ATL) and Chlorthalidone (CTD).The chromatographic separation was achieved by 
using Hypersil- keystone C18 (4.6 x 250mm, 5μm) under isocratic conditions The mobile phase consisted of methanol and triple distilled 
water (80/20, v/v) having pH 7 with a flow rate of 1.0 mL/min. The eluents were monitored at 225 nm for simultaneous measurement.The 
selected chromatographic conditions were found to effectively separate CDP (Rt: 3.25 min), ATL (Rt: 5.366 min) and CTD (Rt: 9.025 min) 
having good resolution. The developed method was validated for linearity, accuracy, precision, LOD, LOQ, robustness and for system 
suitability parameters as per ICH guidelines. In this study, an excellent linearity was obtained with r2 = 0.999, r² = 0.999, r² = 1, for CDP, ATL 
and CTD respectively. The developed chromatographic method proved to be simple, precise, accurate, robust and reproducible Thus, this 
method would be employed for routine simultaneous quantification of CDP, ATL and CTD in bulk form or tablet dosage form. 
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1. INTRODUCTION 
Development of analytical method and validation are the 
continuous and inter-dependent task associated with the 
research and development, quality control and quality 
assurance area. Analytical procedures play important role 
in equivalence and risk assessment, management. It helps 
in establishment of acceptance criteria and stability of 
results. Validation should demonstrate that the analytical 
procedure is suitable for its intended use. Design of 
experiment is a important tool for the method 
characterization and validation. Analytical professionals 
should be comfortable to use it to optimize the analytical 
method. A good analytical method development and its 
validation can provide significant improvements in 
precision and a reduction of errors. It can help to avoid 
costly and time consuming exercises.1 
Cilnidipine (CDP) 1,4-dihydro-2,6-dimethyl-4-(3-
nitrophenyl)-3,5-pyridinecarboxylic acid 2-
methoxyethyl(2e)-3-phenyl-propenyl ester (fig. 1).2 CDP  is  
a  novel  and  unique  1,4-dihydropyridine derivative  
calcium  antagonist  with  potent  inhibitory  actions against  
not  only  L-type  but  also  N-type  voltage dependent 
calcium  channels.3  The  N-type  voltage-dependent  
calcium  channel  plays  an  important  role  in  sympathetic  
neurotransmission  and  regulates  the  release  of 
norepinephrine from sympathetic nerve endings4. It has 
been reported that once-daily administration of CDP 
resulted in a safe and more effective BP decrease in 
essential hypertension without excessive  BP  reduction  or  
reflex  tachycardia  than  similar administration  than  
once-daily  administration  of  nifedipine or nisoldipine.5,6 
 
Figure 1: Structure of Cilnidipine 
Atenolol (ATL), 4-[2-Hydroxy-3-[(1-methylethyl) amino] 
propoxy] phenylacetamide (fig.2) is a selective β1-
adrenoceptor antagonist applied in the treatment of 
numerous cardiovascular disorders such as hypertension 
and angina .The cardio selectivity of ATL is not absolute 
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and at higher doses inhibits β2-adrenergic receptors, 
resulting in bronchospasm. ATL is absorbed quickly but not 
completely by the gastrointestinal tract. After oral 
administration of ATL, approximately 50–60% of the dose 
is absorbed and the rest is excreted unchanged in the feces. 
ATL undergoes little or no metabolism and is eliminated 
primarily by renal excretion.7-8 
 
Figure 2: Structure of Atenolol 
Chlorthalidone (CTD) is a sulphamyl benzophenone 
derivative [2-chloro-5-(1-hydroxyl-3-oxo-2,3-dihydro-1H-
isoindol-1-yl) benzene-1-sulfonamide] (Fig. 3).It is 
a diuretic agent used in the treatment of edema associated 
with congestive heart failure.9  CTD is also used in 
hypertension therapy. This sulphonzunide-like diuretic 
differs chemically from the thiazides by the nature of the 
heterocyclic ring, although its pharmacological action is 
indistinguishable from that of the thiazides.10  
 
Figure 3: Structure of Chlorthalidone 
2. MATERIALS AND METHODS 
2.1 RP-HPLC method 
2.1.1 Materials and reagents  
Cilnidipine from Laksh Fine Chem Pvt. Ltd Anand, Gujarat, 
India Atenolol and Chlorthalidone from Ipca laboratories 
Ratlam Madhya Pradesh India, were received as a gift 
sample. Methanol of HPLC grade from Qualigens fine 
chemicals, Mumbai, India. All the reagents and chemicals 
used were of analytical and HPLC grade. Water (HPLC 
grade) was obtained from Milli Q RO system. 
2.1.2 Instruments and Chromatographic Conditions 
 Waters 600 Controller HPLC system was used for method 
development and validation. Data acquisition was 
performed on Data Ace HPLC software. The separation 
were achieved on C18 (250 × 4.6 mm, 5μm) column at 
ambient temperature and the eluent was monitored at 225 
nm with flow rate of 1.0 mL/min using UV detector. The 
mobile phase mixture of 80 parts Methanol & 20 parts 
Water was filtered through nylon 0.22 μm membrane 
filters and was degassed before use (30 min). A volume of 
20 μL of each sample was injected into column. 
2.1.3 Preparation of standard solution 
The standard stock solutions containing CDP (1000 
μg/mL), ATL (1000 μg/mL) and CTD (600 μg/mL) were 
prepared with methanol. The respective standard sub stock 
solutions containing CDP (100 μg/mL), ATL (100 μg/mL) 
and CTD (60 μg/mL) were prepared separately by 
dissolving with methanol. 1 mL aliquots from the standard 
stock solutions of  CDP, ATL & CTD were transferred to 10 
mL  calibrated volumetric flask and the volume was made 
up to the mark with the same solvent mixture to prepare a 
mixed standard preparation having a concentrations CDP 
(10 μg/mL), ATL (10 μg/mL) and CTD (6 μg/mL). 
Calibration curve solutions containing CDP (10-50 μg/mL), 
ATL (10-50 μg/mL) and CTD (6-30 μg/mL) were prepared 
by diluting the standard stock solution to the appropriate 
volume with the same diluent. 
2.2 Validation of the HPLC method 
2.2.1. System suitability 
The developed method was validated according to ICH 
guidelines11. To check the system performance, the system 
suitability parameters were measured. System precision 
was determined on six replicate injections of standard 
preparations. Number of theoretical plates and asymmetry 
were measured12-13. The system suitability was assured by 
determining peak retention time, peak area, theoretical 
plates and tailing or asymmetry factor for CDP, ATL and 
CTD. The ideal values for system suitability are CV < 1%, 
asymmetry factor < 2 and theoretical plates >200014. Six 
replicate samples were used for determining the system 
suitability. 
2.2.2 Linearity  
Calibration graphs were constructed by plotting peak area 
vs concentration of CDP, ATL and CTD and the regression 
equations were calculated. The calibration graphs were 
plotted over 5 different linear concentrations in the range 
of 10-50 g/mL for CDP, 10-50 g/mL for ATL and 6-36 
µg/mL for CTD. All the solution were filtered through 0.22 
m membrane filter Aliquots (20 μl) of each solution were 
injected under the operating chromatographic condition 
described above [Number of replicates (n = 6)]. A 
calibration graph was plotted between the mean peak area 
Vs respective concentration and regression equation was 
derived. 
2.2.3 Accuracy 
Accuracy is the percent of analyte recovered by assay from 
a known added amount. For the measurement of accuracy 
data from nine determinations over three concentration 
levels covering the specified range were determined 
2.2.4 Precision  
Precision is the degree of repeatability of an analytical 
method under normal operational conditions. The 
precision of the assay was determined by repeatability 
(intra-day) and intermediate precision (inter-day) and 
reported as % R.S.D. for a statistically significant number of 
replicate measurements. The intermediate precision was 
studied by comparing the assays on 3 different days and 
the results documented as standard deviation and 
%R.S.D15. 
2.2.5 LOD and LOQ 
The limit of detection (LOD) is defined as the lowest 
concentration of an analyte that an analytical process can 
reliably differentiate from background levels. The limit of 
quantification (LOQ) is defined as the lowest concentration 
of the standard curve that can be measured with acceptable 
accuracy, precision and variability (ICH guideline Q2B, 
2005). The LOD and LOQ were calculated as 
            
           
 Where σ is the standard deviation of the lowest standard 
concentration and S is the slope of the standard curve. 
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2.2.6 Robustness  
The robustness of the method was evaluated by assaying 
the test solutions after slight but deliberate changes in the 
analytical condition ns like flow rate (+0.1 mL min−1), and 
mobile phase composition (2%). 
3. RESULT AND DISCUSSION 
3.1 System suitability 
In the present HPLC method, methanol and triple distilled 
water (80/20, v/v) were used as mobile phase. In a 
preliminary separate analysis study of CDP, ATL and CTD 
with C18 column was successfully used; therefore, C18 was 
used simultaneous determination. The described 
chromatographic conditions resulted in CDP, ATL and CTD 
retention at about 3.25, 5.36 and 9.02 minutes, According 
to the USP, the HPLC method is considered suitable when 
the CV of peak area < 1%, the tailing factor < 2 and the 
theoretical plates > 2000. The results of system suitability 
are shown in Table 1. All the measured parameters are 
within the recommended limits. Thus, our results 
suggested that the described method was suitable for the 
simultaneous determination of CDP, ATL and CTD. 
Moreover, the analyses of the analyte-containing samples 
exhibited well-differentiated peaks of the analytes at their 
respective retention times, even at the lower 
concentrations. No additional peak, interfering with the 
analyte-peaks, was seen in the chromatogram 
 
Table 1: System suitability 
Parameter CDP ATL CTD 
Peak area 43127.94 36543.81 105615.71 
Retention time 3.25 ± 0.06 5.36 ±0.08 9.02 ±0.08 
Theoretical 
plates 4542 3653 2985 
Tailing factor 1.12 ± 0.04 1.18 ±0.06 1.26 ±0.10 
Each value denotes the mean ±•%CV (n = 6). 
 
 
Figure 4: Overlay UV Spectra of CDP, ATL and CTD 
standard
 
 
Figure 5: Chromatogram of CDP, ATL and CTD standard 
 
3.2 Linearity  
The linearity range for constructing the calibration curves 
for CDP, ATL and CTD were assessed by analysis of 
combined standard solution in range of 10-50 μg/ml, 10-50 
μg/ml and 6-30 μg/ml respectively. The responses were 
linear throughout the range for all three analytes (r2 = 
0.999, r2 = 0.999 and r2 = 1.00, respectively). 
The regression analysis is shown in table  
Table 2: Regression analysis 
 CDP ATL CTD 
Slop  1401 1220 3507 
Intercept 438.2 415.8 274.4 
Correlation coefficient (r2) 0.999 0.999 1.00 
Each value represents the mean ± SD (n = 6). 
 
 
The regression line equation for CDP, ATL and CTD are as 
following:  
For CDP         y = 1401.x + 438.2 and  
For ATL         y = 1220.x - 415.8 and 
For CTD        y = 3507.x + 274.4 
 
Table 3: Linearity data for CDP 
S. No. Concentration Area under curve  
1 10 14233.14 
2 20 28538.94 
3 30 43127.94 
4 40 55929.99 
5 50 70625.85 
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Figure 5: Calibration Graph of CDP 
Table 4: Linearity data for ATL 
S. No. Concentration Area under curve  
1 10 12087.33 
2 20 23368.58 
3 30 36543.81 
4 40 48478.81 
5 50 60577.31 
 
 
Figure 6: Calibration of ATL 
Table 4: Linearity data for CTD 
S. No. Concentration Area under curve  
1 6 21185.59 
2 12 42596.73 
3 18 63473.86 
4 24 84208.88 
5 30 105615.71 
 
 
Figure 7: Calibration of CTD 
3.3 Accuracy  
The accuracy was assessed by the percent recovery 
method. According to the FDA guidelines, the mean value 
should be within 15% of the nominal value, except at LLOQ 
(Lower Limit of quantification), where it should not deviate 
by more than 20%.  
For CDP 
20 μg/mL drug solutions was taken in three different flask 
label A, B and C. Spiked 50%, 100%, 150% of standard 
solution in it and diluted up to 10ml. The area of each 
solution peak was measured at 225 nm. The amount of CDP 
was calculated at each level and % recoveries were 
calculated.  
For ATL 
20 μg/mL drug solutions was taken in three different flask 
label A, B and C. Spiked 50%, 100%, 150% of standard 
solution in it and diluted up to 10ml. The area of each 
solution peak was measured at 225 nm. The amount of ATL 
was calculated at each level and % recoveries were 
calculated. 
For CTD 
12 μg/mL drug solutions was taken in three different flask 
label A, B and C. Spiked 50%, 100%, 150% of standard 
solution in it and diluted up to 10ml. The area of each 
solution peak was measured at 225 nm. The amount of CTD 
was calculated at each level and % recoveries were 
calculated. 
All the accuracy values were within 85–115% of the 
recovery range. Thus, our results suggested that the 
described method was accurate. 
 
Table 6: Statistical data for accuracy 
Statistical data CDP ATL CTD 
% Mean 99.31 98.26 98.00 
SD 0.310 1.023 0.800 
%R.S.D. 0.312 1.041 0.817 
 
3.4 Precision 
Repeatability (Intra-day precision) was studied by 
calculating the relative standard deviation (RSD) for nine 
replicates of mixture having the concentration of 10 μg/mL 
of CDP, 10 μg/mL of ATL , 10 μg/mL of CTD performed on 
the same day and under same experimental conditions. The 
relative standard deviations were calculated for results of 
determinations for each drugs. Inter-day precision studies 
include the estimation of variations in analysis when a 
method is used within laboratories, on different day. The 
SD & RSD values obtained for intraday & inter-day 
precision were summarised in the table. 
 
Table 7: Statistical data for precision 
Statistical parameter 
CDP ATL CTD 
SD % RSD SD % RSD SD % RSD 
Repeatability 0.51 0.51 0.92 0.92 0.74 0.74 
Intermediate Precision 
Day to day 1.18 1.18 0.09 0.09 0.28 0.28 
Analyst to Analyst 0.73 0.73 0.92 0.92 1.28 1.29 
  
y = 1401.8x + 438.23 
R² = 0.9996 
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3.5 Robustness 
As per International Conference of Harmonization norms, 
small, but deliberate variations in concentration of the 
mobile phase were made to test the method’s capacity to 
remain unaffected. The ratio of mobile phase was 
Methanol: Water (pH 7) 80:20 v/v. Change in ratio of 
mobile phase from 78:22 to 82:18 and 80:20 for 
robustness.
 
Table 8: Robustness study of the proposed HPLC method 
Parameter Conditions 
Retention Time 
CDP ATL CTD 
Flow Rate (mL/min) 
 
0.9 3.58 5.85 9.93 
1.0 3.25 5.36 9.02 
1.1 3.03 4.91 8.20 
Mobile Ratio (v/v) 
 
78:22 3.40 5.52 9.10 
80:20 3.25 5.36 9.02 
82:18 3.10 5.20 8.90 
       
4. CONCLUSION 
The present RP-HPLC developed method for simultaneous 
evaluation CDP, ATL and CTD was validated as per ICH 
guideline. The developed RP-HPLC method was found to be 
simple, accurate, rapid selective and precise for the 
concurrent estimation of all three drugs. Hence, there is no 
biased result found by the validated method so method can 
be used for the routine analysis of these three drugs 
simultaneously or any combination of two drugs from 
these three drugs. 
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